TheraRadar
← Back
Data updated: Jul 17, 2026

P AND L DEV LLC

Generics
Pharmaceuticals

P AND L DEV LLC is a generic drug manufacturer with 1 FDA-approved products.

1986
Since
1
Drugs
-
Trials
0
New Drugs (2yr)

Upcoming FDA Decisions

Full Calendar →
Jul 23, 2026 — Rivoceranib + camrelizumab
5d
Jul 23, 2026 — Rivoceranib + camrelizumab
Aug 10, 2026 — Oveporexton (TAK-861)
+2 more dates (Pro)

P AND L DEV LLC's Key Drugs

P AND L DEV LLC's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

P AND L DEV LLC's Recent FDA Approvals

New NDA/BLA approvals for P AND L DEV LLC over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

P AND L DEV LLC's Therapeutic Areas

Disease areas where P AND L DEV LLC has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

P AND L DEV LLC Pipeline Snapshot

Active clinical trials for P AND L DEV LLC across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling